A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy

Cardiac hypertrophy is a common feature in patients with CKD. Recent studies revealed that two phosphate regulators, fibroblast growth factor-23 and α -Klotho, are highly involved in the pathophysiologic process of CKD-induced cardiac hypertrophy. With decreasing renal function, elevated fibroblast growth factor-23 and decreased α -Klotho may contribute to cardiac hypertrophy by targeting the heart directly or by inducing systemic changes, such...